$IBTA

Ibotta (IBTA) Q2 2026 Earnings Call Transcript

Ibotta (IBTA) reported Q2 2026 revenue of $88.9 million, up 3% year over year, and adjusted EBITDA of $16.5 million. Third-party redemption revenue rose 27% to $61.5 million as the company shifted users to its publisher network. Q3 revenue guidance is $86 million to $90 million. Ibotta also said it added 11,500 7-Eleven locations via a partnership.

Original reporting
Published Aug 11, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 4:08 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ibotta (IBTA) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$IBTABullishMed
01

Why it matters

Key decision points for traders are the Q3 revenue and adjusted EBITDA guidance ranges, the implied margin at the midpoint, and the upward revision to full-year free cash flow conversion. The call also highlights a specific commercial catalyst: an exclusive 7-Eleven agreement for digital promotions across 11,500 US locations.

02

Market read

Guidance and conversion metrics (FCF conversion raised to 70% of adjusted EBITDA) are likely to drive the immediate trading reaction, while the disclosed ad revenue pressure is a key counterweight.

03

What to watch

Third-party redeemers and redemptions are growing, but direct-to-consumer redeemer decline is still driving weaker ad revenue; investors may scrutinize whether the third-party mix can fully offset that over multiple quarters.

Relevance 8/10Novelty 8/10Timing: post-market earnings call, guidance for Q3 and full-year FCF conversion

Background

Ibotta’s Q2 2026 call centers on transitioning from direct-to-consumer redeemers toward a third-party publisher network, supported by performance marketing products and retailer partnerships.

Company-level read

Ticker impact

$IBTABullishMedium confidence
Context

Ibotta reported Q2 revenue of $88.9M (+3% YoY) and guided Q3 revenue to $86M-$90M, plus raised full-year free cash flow to 70% of adjusted EBITDA.

Expected impact

Near-term bias upward if investors focus on the raised FCF conversion and third-party redeemer/redemption growth, but ad revenue pressure could cap upside.

Evidence & confidence

Multiple forward-looking datapoints were disclosed (Q3 revenue and adjusted EBITDA guidance, and an upward revision to full-year FCF conversion). However, management also flagged ongoing pressure in ad revenue tied to lower direct-to-consumer redeemers, which can temper the reaction.

Market effects

Reinforces the performance-marketing and digital promotions model shift toward third-party publisher networks, with measurable lift claims used to defend advertiser budgets.

Primarily US-focused given the 7-Eleven partnership and US store footprint.

Limited direct global read-through; mostly a US retail and CPG promotions execution story.

Counterpoint

The headline growth is modest (+3% YoY revenue) while ad and other revenue fell 32% YoY, so the market may treat the guidance as incremental rather than a durable re-acceleration.

Key entities

  • Ibotta

    Reported Q2 2026 results and provided Q3 revenue and adjusted EBITDA guidance, plus raised full-year free cash flow conversion.

  • 7-Eleven, Inc.

    New exclusive agreement for Ibotta to be the third-party provider of CPG digital promotions for 11,500 US store locations.

  • Walmart

    Collaboration to integrate manufacturer-funded savings more deeply into the shopper journey.

  • Circana

    Meta-study partner used to quantify incremental sales lift from Ibotta promotions.

Related articles

$IBTAMed

Ibotta, Inc. (IBTA): Results of Operations and Financial Condition

Ibotta, Inc. (IBTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsrelease63026.htm EX-99.1 Document Ibotta Reports Second Quarter 2026 Financial Results Ibotta’s second quarter financial results exceeded the upper end of the guidance range for both revenue and adjusted EBITDA Revenue grew by 3% year-over-year to $88.9 million

$BKSYMed

BlackSky (BKSY) Q2 2026 Earnings Call Transcript

BlackSky (BKSY) discussed its Q2 2026 earnings call, citing Gen-3 satellite performance and Spectra AI platform. It reported Q2 total revenue up 50% year over year, adjusted EBITDA margin of 14% on $33 million revenue, and $200 million year-to-date bookings. The company raised $150 million, boosting liquidity above $325 million, and said Gen-3 related products drove 90% of growth.

$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

$CDNSMed

CDNS Falls 12.9% in the Past Month. Is the Sell-Off an Opportunity?

Cadence Design Systems (CDNS) shares fell 12.9% over the past month despite Q2 results. According to the company, Q2 revenue rose 24.2% to $1.584B and non-GAAP EPS rose 27.9% to $2.11. The company raised 2026 guidance to $6.26-$6.34B revenue and $8.05-$8.15 EPS, with backlog at a record $8.1B. Valuation remains at 36.3x forward earnings.